Rasmussen et al. did not find a statisticallysignificant correlation between PTX-3 levels and risk of developing cancer in 197 patients with non-specific signs and symptoms, but noted a concluding association between CRP, ESR (erythrocyte sedimentation rate), suPAR (soluble urokinase plasminogen activator receptor), and newly diagnosed cancer [39]. This evidence concerns the gene PTX3 and cancer.